A biotech startup pioneering a unique approach to cancer treatment has just secured $14.0M in Series A funding. KaliVir Immunotherapeutics, founded in 2019, is advancing oncolytic viral immunotherapy, a modality that leverages a virus's natural ability to replicate in and destroy cancer cells.
The company's cutting-edge, next-generation programs combine technologies developed in-house with research licensed from the University of Pittsburgh’s world-class oncolytic virus and immunotherapy programs. This capital infusion will support the continued development of its novel cancer therapies.
